

Giuseppe Petralia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1668990/publications.pdf>

Version: 2024-02-01

88
papers

2,179
citations

257450

24
h-index

243625

44
g-index

91
all docs

91
docs citations

91
times ranked

3148
citing authors

#	ARTICLE	IF	CITATIONS
1	MEtastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	1.9	230
2	CT Perfusion for the Monitoring of Neoadjuvant Chemotherapy and Radiation Therapy in Rectal Carcinoma: Initial Experience. <i>Radiology</i> , 2007, 244, 486-493.	7.3	167
3	Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-enhanced and Diffusion-weighted Magnetic Resonance Imaging Facilitates Detection of Metastases in Normal-sized Pelvic Lymph Nodes of Patients with Bladder and Prostate Cancer. <i>European Urology</i> , 2013, 64, 953-960.	1.9	146
4	Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 326-340.	1.9	132
5	Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 616-624.	2.8	97
6	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 223-239.	3.1	62
7	Dynamic contrast-enhanced MRI in oncology: how we do it. <i>Radiologia Medica</i> , 2020, 125, 1288-1300.	7.7	62
8	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 550-563.	4.4	52
9	Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. <i>Radiologia Medica</i> , 2019, 124, 218-233.	7.7	52
10	Effects of MRI image normalization techniques in prostate cancer radiomics. <i>Physica Medica</i> , 2020, 71, 7-13.	0.7	52
11	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). <i>British Journal of Radiology</i> , 2019, 92, 20180494.	2.2	50
12	Robot-assisted Radical Prostatectomy: Multiparametric MR Imaging-directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. <i>Radiology</i> , 2015, 274, 434-444.	7.3	48
13	Perfusion Computed Tomography for Monitoring Induction Chemotherapy in Patients With Squamous Cell Carcinoma of the Upper Aerodigestive Tract. <i>Journal of Computer Assisted Tomography</i> , 2009, 33, 552-559.	0.9	44
14	Whole body MRI for systemic staging of breast cancer in pregnant women. <i>Breast</i> , 2017, 35, 177-181.	2.2	40
15	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , 2013, 23, 3466-3476.	4.5	39
16	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015, 10, e0139696.	2.5	39
17	Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 421-427.	0.8	38
18	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use. <i>Radiologia Medica</i> , 2021, 126, 1434-1450.	7.7	36

#	ARTICLE	IF	CITATIONS
19	Whole-Body Magnetic Resonance Imaging in Oncology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 495-507.	1.1	32
20	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). <i>European Radiology</i> , 2021, 31, 716-728.	4.5	31
21	Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. <i>European Radiology</i> , 2017, 27, 4372-4378.	4.5	30
22	Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria. <i>Urologia Internationalis</i> , 2016, 96, 459-469.	1.3	27
23	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. <i>Cancer Imaging</i> , 2020, 20, 34.	2.8	27
24	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. <i>British Journal of Radiology</i> , 2020, 93, 20200562.	2.2	26
25	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. <i>Radiology</i> , 2021, 299, 494-507.	7.3	26
26	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 24-35.	4.4	25
27	Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: problem solving by diffusion whole-body MRI. <i>Ecancermedalscience</i> , 2015, 9, 537.	1.1	25
28	Quantification of Variability in Breath-hold Perfusion CT of Hepatocellular Carcinoma: A Step toward Clinical Use. <i>Radiology</i> , 2012, 265, 448-456.	7.3	23
29	Perfusion Computed Tomography in Patients With Hepatocellular Carcinoma Treated With Thalidomide. <i>Journal of Computer Assisted Tomography</i> , 2011, 35, 195-201.	0.9	22
30	The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer. <i>PLoS ONE</i> , 2018, 13, e0205251.	2.5	22
31	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 88-96.	1.9	22
32	Magnetic Resonance Imaging Before Prostate Biopsy: Time to Talk. <i>European Urology</i> , 2016, 69, 1-3.	1.9	21
33	Investigating cancer patient acceptance of Whole Body MRI. <i>Clinical Imaging</i> , 2018, 52, 246-251.	1.5	21
34	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. <i>BJU International</i> , 2020, 126, 104-113.	2.5	21
35	Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. <i>Medicine (United States)</i> , 2016, 95, e4519.	1.0	20
36	Low PI-RADS assessment category excludes extraprostatic extension (pT3a) of prostate cancer: a histology-validated study including 301 operated patients. <i>European Radiology</i> , 2019, 29, 5478-5487.	4.5	20

#	ARTICLE	IF	CITATIONS
37	DCE-MRI and DWI Integration for Breast Lesions Assessment and Heterogeneity Quantification. <i>International Journal of Biomedical Imaging</i> , 2012, 2012, 1-8.	3.9	18
38	Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments. <i>British Journal of Radiology</i> , 2017, 90, 20170021.	2.2	18
39	Whole-body magnetic resonance imaging: technique, guidelines and key applications. <i>Ecanermedicalscience</i> , 2021, 15, 1164.	1.1	18
40	Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 155-163.e6.	1.9	17
41	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. <i>Urologia Internationalis</i> , 2018, 101, 56-64.	1.3	17
42	Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. <i>Tumori</i> , 2016, 102, 536-540.	1.1	15
43	[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning. <i>Lung Cancer</i> , 2008, 61, 362-368.	2.0	14
44	Extramedullary Myeloid Sarcoma of the Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 4041-4043.	1.6	13
45	US-guided transcutaneous tru-cut biopsy of laryngo-hypopharyngeal lesions. <i>European Radiology</i> , 2010, 20, 1450-1455.	4.5	12
46	Future challenges in head and neck cancer: From the bench to the bedside?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, e90-e96.	4.4	12
47	Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020, 20, 77.	2.8	11
48	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. <i>European Urology Open Science</i> , 2021, 27, 19-28.	0.4	11
49	Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. <i>BMC Cancer</i> , 2011, 11, 55.	2.6	9
50	Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. <i>British Journal of Radiology</i> , 2018, 91, 20160725.	2.2	9
51	Radioablation +/androgen hormone therapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019, 19, 903.	2.6	9
52	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 406-413.	3.9	9
53	Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e11-929.e19.	1.6	8
54	Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study. <i>Diagnostics</i> , 2021, 11, 913.	2.6	8

#	ARTICLE	IF	CITATIONS
55	Mixup (Sample Pairing) Can Improve the Performance of Deep Segmentation Networks. <i>Journal of Artificial Intelligence and Soft Computing Research</i> , 2022, 12, 29-39.	4.3	8
56	Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients. <i>Ecanermedalscience</i> , 2014, 8, 476.	1.1	7
57	Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). <i>Medical Oncology</i> , 2020, 37, 74.	2.5	7
58	Preliminary observations regarding the expectations, acceptability and satisfaction of whole-body MRI in self-referring asymptomatic subjects. <i>British Journal of Radiology</i> , 2021, 94, 20191031.	2.2	7
59	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e335-e345.	1.9	7
60	Correlation between CT Perfusion and Clinico-Pathological Features in Prostate Cancer: A Prospective Study. <i>Medical Science Monitor</i> , 2015, 21, 153-162.	1.1	7
61	Sclerosing angiomatoid nodular transformation of the spleen during pregnancy: Diagnostic challenges and clinical management. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1021-1025.	1.3	6
62	Primary focal prostate radiotherapy: Do all patients really need whole-prostate irradiation?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 100-111.	4.4	6
63	Finding Minimal Extraprostatic Disease: Who Cares?. <i>European Urology</i> , 2016, 70, 246-247.	1.9	6
64	A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 315-320.	0.6	6
65	Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021, 11, 499.	2.6	6
66	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	3.7	6
67	Radiologists Should Integrate Clinical Risk Factors with MRI Findings for Meaningful Prostate Cancer Staging. <i>Radiology</i> , 2020, 296, 96-97.	7.3	5
68	ecancermedalscience. <i>Ecanermedalscience</i> , 2014, 8, 429.	1.1	4
69	ecancermedalscience. <i>Ecanermedalscience</i> , 2012, 6, 252.	1.1	4
70	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 94-101.	3.9	4
71	Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison. <i>Tumori</i> , 2022, 108, 263-269.	1.1	4
72	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. <i>BJU International</i> , 2022, 129, 524-533.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. <i>Physica Medica</i> , 2021, 92, 62-68.	0.7	4
74	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 328.	1.1	3
75	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	2.2	3
76	Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II study. <i>Anticancer Research</i> , 2006, 26, 2419-23.	1.1	3
77	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. <i>Scandinavian Journal of Urology</i> , 2020, 54, 382-386.	1.0	2
78	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 732766.	2.8	2
79	Multimodal MRI-based tissue classification in breast ductal carcinoma. , 2012, , .		1
80	Small colorectal cystic metastases to the liver: still a diagnostic dilemma? A report of a case and a review of the literature. <i>Updates in Surgery</i> , 2012, 64, 297-300.	2.0	0
81	One-Step Systemic Staging for Patients with Breast Cancer. , 2017, , 265-276.		0
82	Value Attribution in the Decision to Use of Whole Body MRI for Early Cancer Diagnosis. <i>Diagnostics</i> , 2021, 11, 972.	2.6	0
83	Patients' experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. <i>Ecancermedalscience</i> , 2020, 14, 1127.	1.1	0
84	In-bore MRI targeted biopsy. <i>Acta Biomedica</i> , 2020, 91, e2020012.	0.3	0
85	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. <i>Acta Biomedica</i> , 2021, 92, e2021214.	0.3	0
86	Patients'™ experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. <i>Ecancermedalscience</i> , 2020, 14, 1127.	1.1	0
87	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. <i>Neoplasma</i> , 2022, , .	1.6	0
88	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, , 1.	2.2	0